Obesity is a chronic metabolic disease caused by multiple factors and is considered to be a risk element for type 2 diabetes, cardiovascular disease, hypertension, stroke and various cancers. having a health advertising properties,98,99 which can remove dampness and protect the spleen,100 while reducing NO levels,101 exerting antioxidant effects,38,102 and decreasing the liver lipid content material.103 Its draw out has anti-lipase activity,104 which can directly or indirectly treat obesity. Moreover, given the various biological properties of hesperidin, this phytochemical may have a wider range of biological applications in the future. Therefore, study on natural medicines or foods comprising hesperidin can help expand the range of weight loss and reduce the rate of obesity in the body. Further studies Secretin (rat) on flavonoids similar to hesperidin can better expose the preventive and restorative effects of hesperidin on obesity. Although the hypoglycemic and lipid-lowering activities of hesperidin have been studied in some animals (such as rats) or cells, the lack of clinical trials within the therapeutic effect of hesperidin is definitely a significant limitation that deserves further study. Furthermore, little is known concerning the clinical aspects of this compound, such as bioavailability, the appropriate dose, tolerance and effectiveness of hesperidin and its metabolites for human being disease.15 More investigations should be needed before hesperidin treatment is extended to humans, especially reliable clinical trials, including large-scale, rigorously controlled, and multicenter randomized controlled clinical trials are needed to assess its long-term safety. Acknowledgments We are indebted to our alma mater, Chengdu University or college of Traditional Chinese Medicine for offered convenience in the SRA1 collection of paperwork. Thanks for all the help from everyone in our lab. Consent For Publication All authors have offered consent for publication. Author Contributions Haijun Xiong and Jin Wang are 1st authors and responsible for collecting materials and writing the paper. Qian Ran, Secretin (rat) Guanhua Lou, Chengyi Peng, Qingxia Gan, Ju Hu, Jilin Sun and Renchuan Yao helped with organizing the information and edited in the article pictures. All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work. Funding This research was funded by Secretin (rat) the National Natural Science Foundation Youth Fund (Code: 81102804), Key Research and Development Project of Sichuan Science and Technology Department (Code: 2018SZ0077) Secretin (rat) and Sichuan Colleges and Universities Research Innovation Team Construction Plan Funding (Code: 18TD0017). Disclosure Jilin Sun is the general manager of Sichuan Fuzheng Pharmaceutical Co. Ltd. The authors report no other conflicts of interest in this work..